PHARMA-BIO SERV, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0fde85cd-9c14-4504-ad90-f12842d7f4a5/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $9.0M | 2024-11-01 – 2025-10-31 | evidence 0001654954-26-000710 |
| FY 2024 | $9.5M | 2023-11-01 – 2024-10-31 | evidence 0001654954-25-000915 |
| FY 2023 | $17.0M | 2022-11-01 – 2023-10-31 | evidence 0001654954-24-000996 |
| FY 2022 | $19.4M | 2021-11-01 – 2022-10-31 | evidence 0001654954-23-001018 |
| FY 2021 | $20.1M | 2020-11-01 – 2021-10-31 | evidence 0001654954-22-001532 |
| FY 2020 | $21.6M | 2019-11-01 – 2020-10-31 | evidence 0001654954-21-000973 |
| FY 2019 | $19.5M | 2018-11-01 – 2019-10-31 | evidence 0001654954-20-000889 |
| FY 2018 | $17.8M | 2017-11-01 – 2018-10-31 | evidence 0001654954-19-000854 |
| FY 2017 | $13.3M | 2016-11-01 – 2017-10-31 | evidence 0001654954-19-000854 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PHARMA-BIO SERV, INC. — all facts · Net Income · Operating Income